IncellDx Announces the Expansion of its Companion Diagnostic Program
MENLO PARK, Calif.--(BUSINESS WIRE)--IncellDx, Inc., a privately held molecular diagnostics company, has hired veteran healthcare industry executive, Christine Meda, as Chief Business Officer. In this role, Ms. Meda will oversee the expansion of the Companion Diagnostics team and its operations. She will also join the company’s management team leading the Women’s Health Diagnostic segment of IncellDx.
“Her experience will be invaluable to growing our company as she oversees and helps to accelerate our overall commercialization efforts including our submissions to the Food and Drug Administration.”
"Chris joins our company with over 20 years of management leadership in the healthcare industry, including many years in the field of molecular diagnostics," commented Dr. Bruce Patterson, Chief Executive Officer of IncellDx. “Her experience will be invaluable to growing our company as she oversees and helps to accelerate our overall commercialization efforts including our submissions to the Food and Drug Administration.”
Chris will explore new personalized medicine opportunities with Pharma partners for IncellDx’s unique Cellular Multiplexing™ technology; the first platform to multiplex proteomic and genomic biomarkers with cellular morphology, in a single assay on intact cells. Her extensive experience in Women’s Health diagnostics will be invaluable in opening new markets and applications for IncellDx’s HPV technology that quantifies the overexpression of E6/E7 mRNA within each cell, in addition to the total burden of over expressing cells.
Her executive management experience includes President of Response Genetics; Vice President, Women’s Health at Roche Molecular Diagnostics; Director, Scientific Affairs of Schering AG and Business Unit Manager at Bio-Rad Laboratories.
IncellDx is a molecular diagnostics company dedicated to the detection and monitoring of life threatening viral diseases such as cervical cancer, HIV/AIDS, hepatitis and organ transplant rejection. The company is privately held and located in Menlo Park, California. For more information on IncellDx, please visit our website at www.incelldx.com.